J

Jazz Pharmaceuticals plc
D

JAZZ

120.240
USD
-0.58
(-0.48%)
مفتوح الان
حجم التداول
2,869
الربح لكل سهم
20
العائد الربحي
-
P/E
17
حجم السوق
7,266,037,412
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    0.18
    (0.07%)
    274.00 USD
    AZN
    AZN
    0.195
    (0.29%)
    68.430 USD
    BMY
    BMY
    1.275
    (2.23%)
    58.350 USD
    GSK
    GSK
    0.480
    (1.44%)
    33.920 USD
    LLY
    LLY
    3.34
    (0.44%)
    756.14 USD
    MRK
    MRK
    0.400
    (0.42%)
    95.890 USD
    NVS
    NVS
    1.050
    (1.07%)
    99.250 USD
    PFE
    PFE
    0.260
    (1.00%)
    26.230 USD
    SNY
    SNY
    0.460
    (0.89%)
    51.840 USD
    المزيد
الأخبار
المقالات

العنوان: Jazz Pharmaceuticals plc

القطاع: Healthcare
الصناعة: Biotechnology
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.